Annexon (NASDAQ:ANNX) Director Acquires $138,270.00 in Stock
Annexon, Inc. Director Jung Choi acquired 33,000 shares at $4.19 each, totaling $138,270. The stock's recent performance shows a slight increase, trading at $4.28. Institutional investors have adjusted their stakes, with notable increases from Woodline Partners and Quarry LP. Analysts have mixed ratings, with a consensus of 'Hold' and a price target of $17.33. Annexon is a clinical-stage biopharmaceutical company with its lead candidate ANX005 in various clinical trials.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director Jung Choi bought 33,000 shares of the business's stock in a transaction that occurred on Monday, December 1st. The stock was acquired at an average cost of $4.19 per share, with a total value of $138,270.00. Following the completion of the acquisition, the director owned 33,000 shares of the company's stock, valued at $138,270. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Annexon Stock Performance
NASDAQ ANNX traded up $0.22 on Wednesday, hitting $4.28. 1,759,550 shares of the stock were exchanged, compared to its average volume of 1,800,547. The stock has a fifty day moving average price of $3.32 and a two-hundred day moving average price of $2.72. Annexon, Inc. has a 52-week low of $1.28 and a 52-week high of $5.66. The firm has a market capitalization of $512.02 million, a P/E ratio of -3.04 and a beta of 1.20.
Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.03). Sell-side analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ANNX. CIBC Bancorp USA Inc. purchased a new position in shares of Annexon during the third quarter worth approximately $31,000. Jacobs Levy Equity Management Inc. acquired a new stake in Annexon during the 3rd quarter worth $69,000. Woodline Partners LP grew its position in Annexon by 150.4% during the 3rd quarter. Woodline Partners LP now owns 2,638,275 shares of the company's stock worth $8,047,000 after purchasing an additional 1,584,566 shares during the last quarter. Quarry LP grew its position in Annexon by 155.0% during the 3rd quarter. Quarry LP now owns 110,000 shares of the company's stock worth $336,000 after purchasing an additional 66,867 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in Annexon by 34.8% in the third quarter. Qube Research & Technologies Ltd now owns 572,644 shares of the company's stock valued at $1,747,000 after purchasing an additional 147,924 shares during the period.
Analyst Upgrades and Downgrades
ANNX has been the topic of several recent research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Annexon in a report on Wednesday, October 8th. Zacks Research upgraded Annexon from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. Wells Fargo & Company upped their price target on Annexon from $14.00 to $27.00 and gave the company an "overweight" rating in a research note on Wednesday, November 19th. Finally, HC Wainwright restated a "buy" rating and set a $14.00 price target on shares of Annexon in a research note on Friday, August 15th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $17.33.
Get Our Latest Stock Analysis on Annexon
About Annexon
(Get Free Report)Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than Annexon
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- What is the Nikkei 225 index?
- 3 Stocks You’ll Wish You Bought Before 2026
- Basic Materials Stocks Investing
- Wall Street Punished CrowdStrike for Beating Earnings? Seriously?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Annexon Right Now?
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
